

SDC Table 3. Association of tenofovir exposure with risk\* of alternative kidney disease outcomes

	Demographic-Adjusted Model†		Time-Dependent Cox Model‡		Marginal Structural Model§	
	Hazard Ratio (95% CI)	P Value	Hazard Ratio (95% CI)	P Value	Hazard Ratio (95% CI)	P Value
<b>Doubling of Creatinine (n=432 events)</b>						
Ever Tenofovir	1.40 (1.11-1.75)	<b>0.0039</b>	1.15 (0.88-1.50)	0.31	1.32 (0.99-1.76)	0.058
Cumulative Tenofovir (per year)	1.15 (0.99-1.33)	0.068	1.10 (0.92-1.32)	0.28	1.10 (0.93-1.30)	0.30
<b>CKD <u>and</u> Proteinuria (n=237 events)</b>						
Ever Tenofovir	2.04 (1.51-2.75)	<b>&lt;0.0001</b>	1.69 (1.19-2.39)	<b>0.0032</b>	1.84 (1.30-2.60)	<b>0.0005</b>
Cumulative Tenofovir (per year)	1.46 (1.26-1.69)	<b>&lt;0.0001</b>	1.35 (1.12-1.62)	<b>0.0014</b>	1.35 (1.15-1.58)	<b>0.0002</b>
<b>eGFR-MDRD Decline of 3% or more (n=3246 events)</b>						
Ever Tenofovir	1.52 (1.40-1.66)	<b>&lt;0.0001</b>	1.37 (1.24-1.51)	<b>&lt;0.0001</b>	1.52 (1.37-1.67)	<b>&lt;0.0001</b>
Cumulative Tenofovir (per year)	1.19 (1.12-1.25)	<b>&lt;0.0001</b>	1.11 (1.04-1.18)	<b>0.0014</b>	1.17 (1.10-1.24)	<b>&lt;0.0001</b>
<b>eGFR-MDRD Decline of 5% or more (n=2347 events)</b>						
Ever Tenofovir	1.66 (1.51-1.82)	<b>&lt;0.0001</b>	1.49 (1.33-1.66)	<b>&lt;0.0001</b>	1.65 (1.47-1.85)	<b>&lt;0.0001</b>
Cumulative Tenofovir (per year)	1.22 (1.14-1.29)	<b>&lt;0.0001</b>	1.15 (1.07-1.24)	<b>&lt;0.0001</b>	1.19 (1.12-1.27)	<b>&lt;0.0001</b>

\*Doubling of Creatinine analysis excludes patients who had CKD at baseline. CKD and Proteinuria analysis excludes patients with CKD or proteinuria at baseline.

†Demographic adjusted Cox model includes drug exposure, age, sex, race, and time.

‡Time-dependent multivariable adjusted model includes exposure to tenofovir and all other antiretroviral drugs, age, sex, race, baseline comorbid conditions (diabetes, hypertension, dyslipidemia, prevalent cardiovascular disease, smoking, drug abuse, hepatitis B and C virus infection), baseline measurements (CKD or proteinuria, BMI category), and current measurements (CD4 count, viral load, CKD or proteinuria, lipids, diabetes, and hypertension).

§Marginal structural model includes all baseline variables in multivariable model.